新辅助瘤内顺铂治疗 IV 期 NSCLC 的诊断与治疗一期试验的初步安全性和可行性结果

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2024-03-01 DOI:10.1016/j.jtocrr.2024.100634

Farrah B. Khan MD , Pamela C. Gibson MD , Scott Anderson MD , Sarah Wagner BS , Bernard F. Cole PhD , Peter Kaufman MD , C. Matthew Kinsey MD, MPH

{"title":"新辅助瘤内顺铂治疗 IV 期 NSCLC 的诊断与治疗一期试验的初步安全性和可行性结果","authors":"Farrah B. Khan MD , Pamela C. Gibson MD , Scott Anderson MD , Sarah Wagner BS , Bernard F. Cole PhD , Peter Kaufman MD , C. Matthew Kinsey MD, MPH","doi":"10.1016/j.jtocrr.2024.100634","DOIUrl":null,"url":null,"abstract":"<div><p>Neoadjuvant intratumoral cisplatin has the potential to generate substantial cytotoxicity and immune priming within the tumor environment, while minimizing systemic, off-target, adverse events. We initiated a phase 1A, 3+3 dose-ranging study of neoadjuvant, intratumoral cisplatin, delivered through endobronchial ultrasound bronchoscopy, in the same procedure as the initial diagnosis. There were no dose-limiting toxicity identified at the 20mg level</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 3","pages":"Article 100634"},"PeriodicalIF":3.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000043/pdfft?md5=483f88bb4f86b69307ea20a182f6c519&pid=1-s2.0-S2666364324000043-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC\",\"authors\":\"Farrah B. Khan MD , Pamela C. Gibson MD , Scott Anderson MD , Sarah Wagner BS , Bernard F. Cole PhD , Peter Kaufman MD , C. Matthew Kinsey MD, MPH\",\"doi\":\"10.1016/j.jtocrr.2024.100634\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Neoadjuvant intratumoral cisplatin has the potential to generate substantial cytotoxicity and immune priming within the tumor environment, while minimizing systemic, off-target, adverse events. We initiated a phase 1A, 3+3 dose-ranging study of neoadjuvant, intratumoral cisplatin, delivered through endobronchial ultrasound bronchoscopy, in the same procedure as the initial diagnosis. There were no dose-limiting toxicity identified at the 20mg level</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"5 3\",\"pages\":\"Article 100634\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000043/pdfft?md5=483f88bb4f86b69307ea20a182f6c519&pid=1-s2.0-S2666364324000043-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

新辅助瘤内顺铂有可能在肿瘤环境中产生巨大的细胞毒性和免疫激活作用，同时最大限度地减少全身性的脱靶不良反应。我们启动了一项新辅助瘤内顺铂的 1A 期 3+3 剂量范围研究，该研究通过支气管内超声支气管镜进行，与最初的诊断过程相同。在 20 毫克的剂量水平上，未发现剂量限制性毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC

Neoadjuvant intratumoral cisplatin has the potential to generate substantial cytotoxicity and immune priming within the tumor environment, while minimizing systemic, off-target, adverse events. We initiated a phase 1A, 3+3 dose-ranging study of neoadjuvant, intratumoral cisplatin, delivered through endobronchial ultrasound bronchoscopy, in the same procedure as the initial diagnosis. There were no dose-limiting toxicity identified at the 20mg level

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JTO Clinical and Research Reports Medicine-Oncology

CiteScore

4.20

自引率

0.00%

发文量

145

审稿时长

19 weeks